Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally
Orgenesis (NASDAQ: ORGS) has formed a strategic partnership with Harley Street Healthcare Group (HSHG) to launch a global Longevity & Wellness Initiative. This alliance aims to drive innovation in wellness and longevity, supported by an investment commitment of up to $10 million over 3 years into both Orgenesis and a newly formed joint venture.
The partnership combines Orgenesis' expertise in cell and gene therapies with HSHG's innovative healthcare approach. This collaboration is expected to accelerate the development and accessibility of advanced therapies in the wellness and longevity sectors, potentially opening new markets and revenue streams for Orgenesis.
Orgenesis (NASDAQ: ORGS) ha stretto una partnership strategica con il Harley Street Healthcare Group (HSHG) per lanciare un'iniziativa globale di Longevità e Benessere. Questa alleanza mira a stimolare l'innovazione nel benessere e nella longevità, supportata da un impegno di investimento fino a 10 milioni di dollari in 3 anni sia in Orgenesis che in una nuova joint venture.
La partnership combina l'expertise di Orgenesis nelle terapie cellulari e geniche con l'approccio innovativo alla salute di HSHG. Questa collaborazione dovrebbe accelerare lo sviluppo e l'accessibilità di terapie avanzate nei settori del benessere e della longevità, aprendo potenzialmente nuovi mercati e flussi di entrate per Orgenesis.
Orgenesis (NASDAQ: ORGS) ha establecido una asociación estratégica con el Harley Street Healthcare Group (HSHG) para lanzar una iniciativa global de Longevidad y Bienestar. Esta alianza tiene como objetivo impulsar la innovación en el bienestar y la longevidad, respaldada por un compromiso de inversión de hasta 10 millones de dólares en 3 años en Orgenesis y en una nueva empresa conjunta.
La asociación combina la experiencia de Orgenesis en terapias celulares y genéticas con el enfoque innovador en salud de HSHG. Se espera que esta colaboración acelere el desarrollo y la accesibilidad de terapias avanzadas en los sectores de bienestar y longevidad, abriendo potencialmente nuevos mercados y flujos de ingresos para Orgenesis.
Orgenesis (NASDAQ: ORGS)는 Harley Street Healthcare Group (HSHG)와 전략적 파트너십을 맺고 전 세계 장수 및 웰니스 이니셔티브를 시작했습니다. 이 동맹은 웰니스 및 장수 분야에서 혁신을 촉진하는 것을 목표로 하며, Orgenesis와 새로 형성된 공동 투자 회사에 대해 최대 1천만 달러를 3년 동안 투자하겠다는 약속을 바탕으로 합니다.
이번 파트너십은 Orgenesis의 세포 및 유전자 치료에 대한 전문성과 HSHG의 혁신적인 헬스케어 접근 방식을 결합합니다. 이 협력은 웰니스 및 장수 분야에서 고급 치료의 개발과 접근성을 가속화할 것으로 기대되며, Orgenesis를 위한 새로운 시장과 수익원을 열 가능성이 있습니다.
Orgenesis (NASDAQ: ORGS) a conclu un partenariat stratégique avec le Harley Street Healthcare Group (HSHG) pour lancer une initiative mondiale de Longévité et de Bien-être. Cette alliance vise à stimuler l'innovation dans le bien-être et la longévité, soutenue par un engagement d'investissement pouvant atteindre 10 millions de dollars sur 3 ans dans Orgenesis et dans une nouvelle coentreprise.
Le partenariat combine l'expertise d'Orgenesis dans les thérapies cellulaires et géniques avec l'approche innovante en matière de santé de HSHG. Cette collaboration devrait accélérer le développement et l'accessibilité des thérapies avancées dans les secteurs du bien-être et de la longévité, ouvrant potentiellement de nouveaux marchés et sources de revenus pour Orgenesis.
Orgenesis (NASDAQ: ORGS) hat eine strategische Partnerschaft mit der Harley Street Healthcare Group (HSHG) gegründet, um eine globale Initiative für Langlebigkeit und Wellness zu starten. Diese Allianz soll Innovationen im Bereich Wellness und Langlebigkeit vorantreiben, unterstützt durch ein Investitionsengagement von bis zu 10 Millionen Dollar über 3 Jahre in Orgenesis sowie in ein neu gegründetes Joint Venture.
Die Partnerschaft kombiniert die Expertise von Orgenesis in Zell- und Gentherapien mit dem innovativen Gesundheitsansatz von HSHG. Diese Zusammenarbeit wird voraussichtlich die Entwicklung und Zugänglichkeit von fortschrittlichen Therapien im Bereich Wellness und Langlebigkeit beschleunigen und möglicherweise neue Märkte und Einnahmequellen für Orgenesis erschließen.
- Strategic partnership with Harley Street Healthcare Group to launch a global Longevity & Wellness Initiative
- Investment commitment of up to $10 million over 3 years
- Potential for new market opportunities and revenue streams in wellness and longevity sectors
- None.
Insights
This strategic partnership between Orgenesis and Harley Street Healthcare Group marks a significant move into the growing longevity and wellness market. The
However, investors should note that the wellness and longevity sector is highly competitive and still evolving. The success of this venture will depend on the execution of their innovative strategies and market acceptance. While the partnership offers promising opportunities, it also carries risks associated with entering a new market segment.
Financially, this deal could positively impact Orgenesis' revenue streams and cash flow in the medium to long term, but short-term profitability might be affected due to initial investment costs. Investors should closely monitor the progress of this initiative and its impact on Orgenesis' financial statements in the coming quarters.
The partnership between Orgenesis and Harley Street Healthcare Group represents a significant step towards integrating cell and gene therapies (CGT) into longevity and wellness applications. This move could potentially accelerate the translation of CGT research into practical, consumer-facing treatments.
From a scientific perspective, this initiative could lead to groundbreaking developments in personalized medicine and regenerative therapies. The combination of Orgenesis' expertise in CGT and HSHG's healthcare delivery network creates a unique opportunity to bring cutting-edge treatments directly to consumers.
However, it's important to note that many longevity treatments are still in early stages of research. The effectiveness and long-term safety of these therapies need rigorous scientific validation. Investors should be aware that while this partnership holds promise, the path from research to marketable treatments can be long and uncertain in the biotech sector.
The global wellness economy was valued at
The longevity market, a subset of the wellness industry, is gaining significant traction among high-net-worth individuals and is expanding to broader consumer segments. This partnership could position Orgenesis as a key player in this emerging market, potentially leading to substantial revenue growth if executed effectively.
However, consumer adoption of advanced therapies in the wellness sector can be challenging due to high costs and regulatory hurdles. The success of this venture will largely depend on the partners' ability to navigate these challenges and create accessible, scientifically-backed treatments that resonate with consumers. Investors should closely monitor consumer reception and regulatory developments in this space.
The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to
GERMANTOWN, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced a strategic partnership agreement with Harley Street Healthcare Group (HSHG) – an innovative and forward-looking healthcare provider focused on delivering world-class, proactive, personalized and preventative health & wellness services, based in London with a global presence. This partnership aims to accelerate the clinical development and commercialization of advanced wellness and longevity therapies and products to a global customer base, aimed at significantly reducing the impact of lifestyle-related illnesses on people’s health.
Under the terms of the agreement, Orgenesis and HSHG will establish a joint venture (JV), with Orgenesis owning
The JV intends to introduce a suite of wellness and longevity products by the end of 2024 that will include immune cell banking, aging and longevity therapies, preventative illness screening, and regenerative therapies using stem cells. The initial rollout will target key global regions, including the United Kingdom, UAE, MENA, Canada, ASEAN, the Balkans, Africa, Latam, and the Indian subcontinent.
In connection with the agreement, HSHG has agreed to invest up to
Vered Caplan, CEO of Orgenesis, commented, “This partnership with Harley Street Healthcare Group marks a significant milestone in Orgenesis’ strategy to expand our footprint in the global wellness market. By combining our expertise in cell and gene therapies with HSHG’s clinical excellence, we are poised to deliver innovative health solutions and our goal will be to redefine patient care and longevity. Importantly, Harley Street has demonstrated its commitment to the JV through a direct investment in both Orgenesis and the JV. We could not be more excited about this collaboration and its potential to rapidly deploy cutting-edge, longevity-focused health and wellness services.”
Sanjeev Kumar, Founder & Chief Visionary Officer of Harley Street Healthcare Group, added, “In our mission to making 90 the new 50 a reality, we are thrilled to collaborate with Orgenesis and have Vered and her team be our strategic partners in this transformative venture. I believe that our shared vision of enhancing health outcomes through innovative therapies and services will pave the way for a new era in personalized medicine and preventative care.”
About Harley Street Healthcare Group
Harley Street Healthcare Group (HSHG), including its brands and subsidiaries, the Harley Club and HARLEY of LONDON, provides integrated health & wellness services to its global client base by bringing together the best of modern medicine, state-of-the-art technological innovations wrapped around the resourcefulness of ancient healing systems. Based in London with a growing global presence, HSHG is focused on being an invested partner in the health & wellness journey of its customers through a proactive, personalized and preventative approach to delivering healthcare, moving away from the current industrial sick care system.
More information on the group is available at:
www.theharleyclub.com, www.harleyoflondon.co.uk
About Orgenesis
Orgenesis is a global biotech company that has been committed to unlocking the potential of cell and gene therapies (CGTs) since 2012 as well as a paradigm-shifting decentralized approach to processing since 2020. This new model allows Orgenesis to bring academia, hospitals, and industry together to make these essential therapies a reality sooner rather than later. Orgenesis is focusing on advancing its CGTs toward eventual commercialization, while partnering with key industry stakeholders to provide a rapid, globally harmonized pathway for these therapies to reach and treat a larger numbers of patients more cost effectively and with better outcomes through great science and decentralized production. Additional information about the Company is available at: www.orgenesis.com.
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, the timing and amount of HSHG’s investment in our securities, our ability to successfully implement this joint venture with HSHG, the potential delisting of our securities from Nasdaq, our ability to secure additional capital, our reliance on, and our ability to grow our point-of-care cell therapy platform, our ability to achieve and maintain overall profitability, our ability to manage our research and development programs that are based on novel technologies, our ability to control key elements relating to the development and commercialization of therapeutic product candidates with third parties, the timing of completion of clinical trials and studies, the availability of additional data, outcomes of clinical trials of our product candidates, the potential uses and benefits of our product candidates, the sufficiency of working capital to realize our business plans and our ability to raise additional capital, the development of our POCare strategy, our trans differentiation technology as therapeutic treatment for diabetes, the technology behind our in-licensed ATMPs not functioning as expected, our ability to further our CGT development projects, either directly or through our JV partner agreements, and to fulfill our obligations under such agreements, our license agreements with other institutions, our ability to retain key employees, our competitors developing better or cheaper alternatives to our products, risks relating to legal proceedings against us and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.
IR contact for Orgenesis:
Crescendo Communications, LLC
Tel: 212-671-1021
Orgs@crescendo-ir.com
Communications contact for Orgenesis
IB Communications
Neil Hunter / Michelle Boxall
Tel +44 (0)20 8943 4685
neil@ibcomms.agency / michelle@ibcomms.agency
FAQ
What is the new partnership announced by Orgenesis (ORGS) on August 14, 2024?
How much is the investment commitment for the Orgenesis (ORGS) and Harley Street Healthcare Group partnership?
What is the main goal of the Orgenesis (ORGS) and Harley Street Healthcare Group partnership?
